EX-FILING FEES 8 tm249930d1_ex-filingfees.htm EX-FILING FEES

 

Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Outlook Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

 

Security

Type

 

Security

Class

Title

 

Fee

Calculation

or Carry

Forward

Rule

 

Amount

Registered 

 

Proposed

Maximum 
Offering

Price Per

Unit

 

Maximum

Aggregate

Offering

Price

 

Fee

Rate

 

Amount of

Registration

Fee

 

Carry

Forward 

Form

Type

 

Carry

Forward

File

Number

 

Carry

Forward

Initial

effective

date

 

Filing Fee

Previously

Paid In

Connection

with

Unsold

Securities

to

be Carried

Forward

 

Newly Registered Securities

Fees to Be

Paid

 

Equity

Common

Stock,

par

value $0.01 

per

share(1)

 

                   
  Equity

Preferred

Stock,

par

value

$0.01

per

share(1)

 

                   
  Debt

Debt

Securities(1)

 

                   
  Other Warrants(1)                    
 

Unallocated 

(Universal)

Shelf

 

Rule 457(o) (2) (3) $116,585,361 0.00014760 $17,208        

Fees

Previously 

Paid

 

       
Carryforward Securities

Carry

Forward

Securities

 

Equity

Common

Stock,

par

value

$0.01

per

share(1)

 

  (4)   $93,731,868 0.0001091   S-3 333-254778 April 1, 2021 $10,227
  Equity

Preferred

Stock,

par

value

$0.01

per

share(1) 

 

                   
  Debt

Debt

Securities(1) 

 

                   
  Other Warrants(1)                    
 

Unallocated

(Universal)

Shelf

 

Unallocated

(Universal)

Shelf

 

(4)   $89,682,771 0.0001091   S-3 333-254778 April 1, 2021 $9,784
  Total Offering Amounts    $300,000,000   $17,208        
  Total Fees Previously Paid               
  Total Fee Offsets               
  Net Fee Due        $17,208        

 

 

 

 

(1) Separate consideration may or may not be received for securities that are issuable upon the conversion or exercise of, or in exchange for, other securities offered hereby.

 

(2) Outlook Therapeutics, Inc. (the “Registrant”) is registering hereunder such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities to be sold by the Registrant from time to time at unspecified prices which shall have an aggregate initial offering price not to exceed $300,000,000. If any debt securities are issued at an original issue discount, then the principal amount of such debt securities shall be in such greater amount as shall result in an aggregate initial offering price not to exceed $300,000,000, less the aggregate dollar amount of all securities previously issued hereunder. The securities registered for sale also include such indeterminate number of shares of common stock and preferred stock as may be issued upon conversion of debt securities, such indeterminate number of shares of common stock that may be issued upon conversion of preferred stock and such indeterminate number of shares of common stock and preferred stock and principal amount of debt securities that may be issued upon exercise of warrants. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares being registered hereunder include such indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions.

 

(3) The proposed maximum offering price per share will be determined, from time to time, by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to Instruction 2.A.iii.b. to the Calculation of Filing Fee Tables and Related Disclosure on Item 16(b) of Form S-3 under the Securities Act.

 

(4) Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include $183,414,639 of unsold securities (the “Unsold Securities”) previously registered pursuant to the Registration Statement on Form S-3 (File No. 333-254778), which was declared effective on April 1, 2021 (the “Prior Registration Statement”), which includes $93,731,868 of unsold common stock pursuant to a prospectus supplement, dated May 16, 2023, to the Prior Registration Statement relating to the Registrant’s “at-the-market” offering pursuant to a sales agreement. In connection with the filing of the Prior Registration Statement, the registrant paid a filing fee of $20,011 associated with the offering of the Unsold Securities (based on the filing fee rate in effect at the time of the filing of the Prior Registration Statement). The filing fee associated with the offering of the Unsold Securities is hereby carried forward to be applied to the Unsold Securities registered hereunder, and no additional filing fee is due with respect to the Unsold Securities in connection with the filing of this Registration Statement. The registrant is also registering new securities on this registration statement with an aggregate initial offering price of $116,585,361 (the “New Securities”), which aggregate offering price is not specified as to each class of securities. A filing fee of $17,208 with respect to the New Securities is being paid in connection with the filing of this registration statement. To the extent that, after the filing date hereof and prior to the effectiveness of this registration statement, the registrant sells any Unsold Securities pursuant to the Prior Registration Statement, the registrant will identify in a pre-effective amendment to this registration statement the updated number of Unsold Securities from the Prior Registration Statement to be included in this registration statement pursuant to Rule 415(a)(6) and the updated amount of new securities to be registered on this registration statement. Pursuant to Rule 415(a)(6), the offering of securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration statement.